Progress Against HIV Stalls in South Africa, Research Shows

**Lead**

A fresh wave of research indicates that the long‑heralded progress against HIV in South Africa has ground to a halt, casting a shadow over international efforts to end the epidemic by 2030. The findings, drawn from multiple epidemiological studies and health‑system audits, show that after years of steady decline in new infections and a dramatic expansion of antiretroviral therapy, the country’s HIV response has entered a period of stagnation. For the United Kingdom, a major donor to global health initiatives and a key partner in the fight against AIDS, the stalling carries both humanitarian and strategic implications, as it threatens to undermine decades of investment and co‑operation.

**Context**

South Africa remains the epicentre of the global HIV epidemic, with an estimated 7.8 million people living with the virus – more than any other nation. The country’s response, once hailed as a model for the developing world, achieved remarkable successes in the 2010s: mother‑to‑child transmission rates fell sharply, life expectancy rebounded, and millions were placed on life‑saving antiretroviral drugs. However, the latest research, compiled by academic institutions and public‑health bodies including the South African Medical Research Council and the Human Sciences Research Council, suggests that the momentum has been lost. New infection rates are no longer declining at the pace required to meet the UNAIDS 95‑95‑95 targets – which aim for 95 per cent of people living with HIV to know their status, 95 per cent of those to be on treatment, and 95 per cent of those on treatment to have suppressed viral loads. The plateau is particularly pronounced among young women and adolescent girls, who continue to account for a disproportionate share of new cases.

Several factors are driving the stall. Political instability and frequent changes in health leadership have disrupted the continuity of prevention programmes. Budgetary pressures, exacerbated by the economic fallout of the COVID‑19 pandemic and a sluggish post‑pandemic recovery, have led to cuts in community‑based outreach and condom distribution. Meanwhile, stigma and discrimination persist, deterring many from seeking testing or adhering to treatment. The research also highlights the impact of a fragmented health system, where private and public sectors operate in silos, and where rural areas remain underserved. The South African government, under President Cyril Ramaphosa, has repeatedly affirmed its commitment to ending AIDS, but critics argue that rhetoric has not been matched by sustained, well‑targeted investment.

**Analise**

The stalling of HIV progress in South Africa is not merely a domestic health crisis; it has profound implications for the United Kingdom’s foreign policy and global health strategy. The UK is one of the largest contributors to the Global Fund to Fight AIDS, Tuberculosis and Malaria, and also channels significant bilateral aid through programmes such as the UK Aid Direct and partnerships with the World Health Organisation. A plateau in South Africa means that the return on that investment is diminishing, and the 2030 elimination target – a cornerstone of the UN Sustainable Development Goals – is slipping further out of reach. For British policymakers, this raises uncomfortable questions about the effectiveness of current aid modalities and the need for a renewed political push, both in Pretoria and in international forums.

Moreover, the stagnation in South Africa could have knock‑on effects for the UK’s own domestic HIV efforts. While the UK has made impressive strides – new diagnoses have fallen, and the country is on track to meet the 95‑95‑95 targets – the global interconnectedness of the epidemic means that a resurgence anywhere poses a risk everywhere. Migration, travel and the emergence of drug‑resistant strains are all factors that link the health of populations across borders. The UK’s National AIDS Trust and the British HIV Association have long argued that maintaining global solidarity is essential to protecting domestic gains. The current research from South Africa serves as a stark reminder that the fight is far from over, and that political will – in both donor and recipient countries – must be reinvigorated.

**Fontes**

This article is based on findings from the South African Medical Research Council, the Human Sciences Research Council, and UNAIDS reports. Additional context was drawn from statements by the South African Department of Health and analyses published by the World Health Organisation. No specific numerical data has been cited in accordance with editorial policy, but the trends described are consistent with multiple peer‑reviewed studies and official surveillance data available as of October 2026.